TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03892824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vine™ Embolic Protection System
Description: The system includes the implant and the Vine™ Inserter (inserter) manufactured by Javelin Medical LTD (Israel). The inserter comprises a Motor Unit and a Needle Unit (Needle Unit) available in two sizes. The system is operable when the Needle Unit is loaded with the implant (labeled Loaded Needle Unit) and connected to the Motor Unit. A flag indicating the needle orientation is attached to the needle luer. The implant is automatically deployed from the needle upon activation of the operating button.
Study: NCT05019586

Intervention type: DRUG
Intervention: levofloxacin, amoxicillin, clarithromycin
Description: Triple therapy of Helicobacter pylori including two antibiotics and a proton inhibitor for 10 days

Intervention type: DRUG
Intervention: levofloxacin, amoxicillin, clarithromycin
Description: Triple therapy of Helicobacter pylori including two antibiotics and a proton inhibitor for 10 days
Study: NCT02615041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: 1 g in 100 ml of normal saline solution and administered via bolus injection Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 hh after 3rd dose of meropenem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: 1 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and~1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: 2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem.
Study: NCT01218646

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Trivalent Inactivated Influenza Vaccine, No Preservative
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative
Description: 0.5 mL, Intramuscular
Study: NCT03360500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXERCISE PROTOCOL + CRYOTHERAPY
Description: Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.~Cryotherapy: Crushed ice inside two plastic bags. The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXERCISE PROTOCOL
Description: Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EXERCISE PROTOCOL + PLACEBO
Description: Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.~Placebo: Sand inside two plastic bags. The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the sandbags, they will be fixed with an elastic bandage (compression). All the knee surface will be covered with a moistened operative field.
Study: NCT02375243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: dexmedetomidine continous infusion 0.5 mcg/kg/h
Study: NCT06526442

Intervention type: DIAGNOSTIC_TEST
Intervention: magnetic resonance imaging
Description: all participants undergo novel MR sequences, including 3D-MRE，DCE-MRI，IVIM-DWI，T1/T2 mapping.

Intervention type: DIAGNOSTIC_TEST
Intervention: magnetic resonance imaging
Description: all participants undergo novel MR sequences, including 3D-MRE，DCE-MRI，IVIM-DWI，T1/T2 mapping.
Study: NCT02451982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 200 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 200 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 200 mg/m2 IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX pancreatic cancer
Description: 5x10\^8 cells intradermal injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX pancreatic cancer
Description: 5x10\^8 cells intradermal injection
Study: NCT03925025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Treatment in addition to standard therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimodipine
Description: Treatment in addition to standard therapy
Study: NCT03963739

Intervention type: OTHER
Intervention: Interview
Description: Undergo interview

Intervention type: OTHER
Intervention: Interview
Description: Undergo interview

Intervention type: OTHER
Intervention: Interview
Description: Undergo interview

Intervention type: OTHER
Intervention: Interview
Description: Undergo interview

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04018937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab will be administered by either subcutaneous (SQ) injection or IV. A test dose of alemtuzumab, 3 mg, is administered on the first day. If the test dose is tolerated, administration of three treatment doses will begin within 24 hours. The three treatment doses will be administered on consecutive days. On the first day, 10 mg/m2 will be given, 15 mg/m\^2 the second and 20 mg/m\^2 the third. Alemtuzumab will be started between Days -22 and -20, but all doses (test dose and three treatment doses) should be completed by Day -18.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered at 30 mg/m\^2 IV daily for five days (Days -7 to -3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan will be administered at 140 mg/m\^2 IV on Day -3 following fludarabine administration.
Study: NCT02509819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heel Cushion Material Bulk (foam)
Description: The heel wedge is made of a rubber style urethane foam. Heel wedges of specified heights and durometers will be inserted into the standard shoes, one at a time, during the test session only. The heel wedges used during the test session are made of the same foam as the heel wedges that are used clinically.
Study: NCT01628432

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conservative hysterectomy I
Description: conservative hysterectomy for benign disease

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative hysterectomy II
Description: bilateral salpingectomy during hysterectomy without conservation of the ovaries
Study: NCT01472861

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AECC (Autologous endometrial coculture)
Description: endometrial biopsy with autologous endometrial coculture

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no endometrial biopsy or Autologous endometrial coculture (AECC) performed
Description: routine procedures with out biopsy
Study: NCT02675036

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Study: NCT00762710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin medication
Description: Form: Prazosin will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo medication
Description: Form: Placebo will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg
Study: NCT01244438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-1039
Description: FP-1039 will be administered at a dose up to 16 mg/kg intravenously over 30 minutes once a week.
Study: NCT04405037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvimopan
Description: Alvimopan will be given to patients who are diagnosed with postoperative ileus after surgery
Study: NCT01729390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy density and portion size feeding study
Description: In a crossover design, adults are served breakfast and lunch, 1 day a week for 6 weeks. Breakfast is not varied across weeks. At 4 of the lunch meals, a salad first course will be served that needs to be eaten in its entirety. At these 4 meals the lunch entree will vary in energy density (100% and 133%) and portion size (100% and 133%). At the 2 lunch meals for which no first course is served, the lunch entree will be vary in energy density (100% and 133%) but be the same portion size (133%).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy density and portion size feeding study
Description: In a crossover design, adults are served breakfast and lunch, 1 day a week for 6 weeks. Breakfast is not varied across weeks. At 4 of the lunch meals, a salad first course will be served that needs to be eaten in its entirety. At these 4 meals the lunch entree will vary in energy density (100% and 133%) and portion size (100% and 133%). At the 2 lunch meals for which no first course is served, the lunch entree will be vary in energy density (100% and 133%) but be the same portion size (133%).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy density and portion size feeding study
Description: In a crossover design, adults are served breakfast and lunch, 1 day a week for 6 weeks. Breakfast is not varied across weeks. At 4 of the lunch meals, a salad first course will be served that needs to be eaten in its entirety. At these 4 meals the lunch entree will vary in energy density (100% and 133%) and portion size (100% and 133%). At the 2 lunch meals for which no first course is served, the lunch entree will be vary in energy density (100% and 133%) but be the same portion size (133%).
Study: NCT02451982

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX pancreatic cancer
Description: 5x10\^8 cells intradermal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480 mg IV
Study: NCT03332355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-1 Compound
Description: PAC-1 in combination with temozolomide (Component 2): after the MTD is established for single agent PAC-1 in Component 1, a modified-Fibonacci dose-escalation 3+3 design starts in Component 2, at a PAC-1 dose one level lower than the MTD of PAC-1 established in the single agent PAC-1 component (i.e., Component 1). PAC-1 will be taken in the morning on days 1-21 in each 28 day cycle. Temozolomide 150 mg/m2 dose is given for the 5 days starting at day 8 of cycle 1 in cohorts of 3-6 patients. The combination cohort that reaches MTD will expanded to at least 9 patients, similar to the PAC-1 alone cohort at MTD.
Study: NCT02451982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480 mg IV
Study: NCT01090778

Intervention type: DRUG
Group type: OTHER
Intervention: Norditropin SimpleXx (growth hormone)
Description: 3mg/subject/day over two consecutive days

Intervention type: DRUG
Group type: OTHER
Intervention: Norditropin SimpleXx (growth hormone)
Description: 3mg/subject/day over two consecutive days

Intervention type: DRUG
Group type: OTHER
Intervention: Norditropin SimpleXx (growth hormone)
Description: 3mg/subject/day over two consecutive days

Intervention type: DRUG
Group type: OTHER
Intervention: Norditropin SimpleXx (growth hormone)
Description: 3mg/subject/day over two consecutive days
Study: NCT00576589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE-326,597
Description: CE-326,597 administered orally, once daily for 14-days at 1 to 2 doses (25 mg QD, 100 mg QD) with the morning meal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: CE-326,597 matching placebo administered orally, once daily for 14-days with the morning meal.
Study: NCT02075567

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental
Study: NCT02655614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0134
Description: GDC-0134 capsule will be administered orally at various doses, depending on the cohort and treatment period.

Intervention type: DRUG
Group type: OTHER
Intervention: GDC-0134
Description: GDC-0134 capsule will be administered orally at various doses, depending on the cohort and treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0134
Description: GDC-0134 capsule will be administered orally at various doses, depending on the cohort and treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to GDC-0134

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to GDC-0134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole 20 mg twice daily orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rabeprazole
Description: Rabeprazole 20 mg twice daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 2mg of liquid formulation of midazolam orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: 2mg of liquid formulation of midazolam orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 100 mg tablet or solution of caffeine orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine
Description: 100 mg tablet or solution of caffeine orally
Study: NCT02764892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V81444
Description: Single oral dose of V81444
Study: NCT03290976

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture treatments will be patient-tailored, with the acupuncture points (acu-points) to be selected by the acupuncturist at each treatment session, in accordance with the dynamic of the patient's symptoms, concerns and expectations. At the same time, acupuncturists will be required to choose at least 5 of the following 11 acupoints, which are to be incorporated into their treatment regimen:~Lower limb points: Liver (LIV) 3, Spleen (SP) 4, SP6, Stomach (ST) 36, Gallbladder (GB) 34, Kidney (KID) 3, LIV8, Web (Bafeng) points Upper limb points: Large Intestine (LI) 4, LI 11, LI10, Pericardium (PC) 6, Triple Warmer (TW) 3/4/5

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture treatments will be patient-tailored, with the acupuncture points (acu-points) to be selected by the acupuncturist at each treatment session, in accordance with the dynamic of the patient's symptoms, concerns and expectations. At the same time, acupuncturists will be required to choose at least 5 of the following 11 acupoints, which are to be incorporated into their treatment regimen:~Lower limb points: Liver (LIV) 3, Spleen (SP) 4, SP6, Stomach (ST) 36, Gallbladder (GB) 34, Kidney (KID) 3, LIV8, Web (Bafeng) points Upper limb points: Large Intestine (LI) 4, LI 11, LI10, Pericardium (PC) 6, Triple Warmer (TW) 3/4/5

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multi-modality (Acupuncture plus)
Description: A number of additional CIM treatment modalities will be added to the acupuncture treatment in this arm of the study, in accordance with the practitioners available at each of the participating study centers. These will include one of more of the following:~* Manual-movement therapies - e.g. acupressure/reflexology, self- and caregiver-practiced acupressure~* Mind-body therapies - e.g. relaxation/imagery method, Anthroposophic music therapy The multimodal CIM treatment regimen will be re-evaluated at each session, and adapted according to the concerns and expectations of the patients, as well as the recommendation of the treating CIM practitioner.
Study: NCT02451982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urelumab
Description: 8 mg IV
Study: NCT03328468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercise
Description: Breathing exercise for stroke patients
Study: NCT03669640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6889450
Description: Participants will receive a once-daily, oral dose of RO6889450 for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6889450
Description: Participants will receive a once-daily, oral dose of RO6889450 for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a once-daily, oral dose of placebo matched to RO6889450 for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a once-daily, oral dose of placebo matched to RO6889450 for 12 weeks.
Study: NCT00049010

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: comparative genomic hybridization

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study: NCT03035981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White rice, low amylose
Description: White and brown rice were tested for differences in gastric emptying rate and appetitive response

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White rice, high amylose
Description: White and brown rice were tested for differences in gastric emptying rate and appetitive response

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White rice, slow
Description: White and brown rice were tested for differences in gastric emptying rate and appetitive response

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White rice, resistant
Description: White and brown rice were tested for differences in gastric emptying rate and appetitive response

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brown rice, low amylose
Description: White and brown rice were tested for differences in gastric emptying rate and appetitive response

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brown rice, high amylose
Description: White and brown rice were tested for differences in gastric emptying rate and appetitive response

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructooligosaccharide (FOS)
Description: White and brown rice were tested for differences in gastric emptying rate and appetitive response
Study: NCT02830646

Intervention type: OTHER
Group type: OTHER
Intervention: DFG mesure
Description: Measure the effect of gastric bypass on the report DFG / VEC.
Study: NCT02487407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-109
Description: ODM-109 1 mg capsule for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ODM-109
Description: ODM-109 1 mg capsule for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ODM-109
Description: Placebo capsule for oral administration.
Study: NCT01051310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic CoreValve System
Description: Transcatheter Aortic Valve
Study: NCT02451982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986253
Description: 2400 mg IV